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Abstract
Purpose: To investigate the efficacy of prednisone for treatment of withdrawal headache in patients with medication
overuse headache (MOH).
Patients and methods: In this prospective double-blind, placebo-controlled, parallel designed multicentre trial, 96 con-
secutive patients with MOH were randomized to withdrawal treatment with either 100 mg prednisone or placebo over 5
days. Patients were enrolled if they met the International Headache Society criteria for MOH and were diagnosed with
migraine or episodic tension-type headache as primary headache. Exclusion criteria comprised significant neurological or
psychiatric disorders. Withdrawal symptoms, including headache severity and intake of rescue medication, were docu-
mented for 14 days after randomization.
Results: Patients treated with prednisone did not experience fewer hours of moderate or severe headache than patients
receiving placebo. However, patients requested less rescue medication within the first 5 days.
Conclusions: During withdrawal in MOH, prednisone reduces rescue medication without decreasing the severity and
duration of withdrawal headache.
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Introduction
Medication overuse headache (MOH) is a widespread
disorder with a prevalence of about 1–2% in the general
population (1). Medication overuse headache is usually
diagnosed in patients with primary headache, such as
migraine or tension-type headache, who develop daily
or nearly daily headache on at least 15 days per month
following overuse of acute headache medication (2).
Treatment of choice for MOH is based on abrupt or
gradual withdrawal of overused medication; however,
this results in severe rebound headache and additional
symptoms like nausea, arterial hypotension, tachycar-
dia, sleep disturbances, anxiety, restlessness and ner-
vousness in many patients (3). Treatment options for
withdrawal headache are limited (4–6). Prednisone is
suggested for treatment of withdrawal headache,
but studies so far have provided mixed results (7–10).
In this multicentre, double-blind, randomized, placebo-
controlled trial, we aimed to evaluate the efficacy of
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prednisone in the treatment of withdrawal headache in
patients with MOH.
Methods and patients
Patients were enrolled if they met the International
Headache Society criteria for MOH (11) and were diag-
nosed with migraine or episodic tension-type headache
as primary headache. Exclusion criteria comprised sig-
nificant neurological, psychiatric or other disorders and
contraindications for treatment with prednisone
according to the German SPC. Pregnant and breast-
feeding women were excluded. Patients gave written
consent after oral and written information. The local
ethics committees of all participating centres approved
the study. Patients were recruited from and included at
headache clinics of the neurological departments of the
university hospital of Essen, Luther-University Halle-
Wittenberg, Ludwig-Maximilians-University Munich
in Germany and in the Department of Neurology and
Pain Medicine, Upper Austrian Headache Centre, of
Konventhospital Barmherzige Brueder, Linz in
Austria. Patient enrolment was relatively low, possibly
because no allowance was paid for enrolment and par-
ticipation in the trial.
Study design
The study was designed as a double-blind, placebo-
controlled, randomized, parallel multicentre trial. A
sample size of 96 patients (48 placebo, 48 verum) was
allocated based on biometric calculations. A reduction
of 20% of hours with moderate or severe headache
during 5 days of withdrawal was expected. Interim ana-
lyses were planned per protocol after inclusion of 32 and
64 patients to allow premature assessment of significant
differences. No significant differences were found.
Due to changing routine in the treatment of MOH
patients, the protocol was adapted after inclusion of
nine subjects. Patients could undergo withdrawal ther-
apy not only as inpatients (as initially planned), but
also on an outpatient basis.
Placebo or prednisone 100mg, each in two tablets,
was given once daily during the first 5 days of with-
drawal. In addition, all patients were treated with cal-
cium, potassium and 300mg ranitidin per day. The
medication was blinded and randomized in a block
size of four by standardized computer-based random-
ization software and delivered by the pharmacy of the
University Hospital of Essen. Two of four consecutive
patients received placebo and two received verum. Only
the pharmacist was not blinded to treatment.
Patients were allowed to take rescue medication in
case of unbearable headache, but were instructed to
limit it as far as possible. The treating physician
assessed dose and type of rescue medication. The fre-
quency of intake of individual rescue medication was
assessed. Prophylactic medication could be started
during withdrawal. Severity of headache was docu-
mented as an average value every hour in a diary
using a four-point scale (0¼none, 1¼mild, 2¼moder-
ate, 3¼ severe headache) for 14 days. Documentation
was interrupted during sleep. Patients were provided
with stamped, addressed envelopes and asked to
return diaries after completion. Patients were not
asked to return to the clinic after completion of the
headache diary. The primary endpoint was the
number of hours with severe or moderate headache
within the first 3 days of withdrawal. Secondary end-
points were the number of hours with severe or mod-
erate headache within the first 5 and 14 days of
withdrawal, and rescue medication used in each
group. In addition, analogous to Bøe et al. (9), a
mean headache index (MHI) was calculated based on
the mean intensity of headache during withdrawal
and days of withdrawal. MHI¼ (a * 1þb * 2þ c * 3)/
number of hours recorded, where ‘a’ refers to number
of days with mild headache, ‘b’ refers to number of
days with moderate headache and ‘c’ refers to number
of days with severe headache.
Statistical analysis
We comparedmean values (age; period of primary head-
ache; headache during the last 3 months; hours with
severe or moderate headache within 3, 5 and 14 days;
hours withmild, moderate or severe headache within 3, 5
or 14 days; rescue medication (intake frequency) within
5 and 14 days) between groups (prednisone; placebo)
using independent-samples t-test and ratios (sex; pri-
mary headache; management) between groups using
the Mann-Whitney-U-test. We performed ANOVA for
repeated measurements to comparemoderate and severe
headache per day between groups (within-subjects vari-
able TIME: hours with headache on days 1–3, 3–5 and
6–14); between-subjects variable GROUP: placebo,
prednisone). All statistical calculations were performed
using the software PASW statistics version 18 for
Windows. The level of significance was set at 0.05.
Bonferroni correction was performed if appropriate.
Results
Patient population
Ninety-six patients (48 patients in each group) aged
18–68 years (mean (SD) 41 (12) years) were included
between June 2004 and June 2009 in three centres in
Germany (Neurological Departments of the University
Hospitals of Essen, Halle (Saale) and Munich) and one
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centre in Austria (Department of Neurology and Pain
Medicine, Upper Austrian Headache Centre,
Konventhospital Barmherzige Brueder, Linz). Data
for the primary endpoint were available for 78 patients
(37 in the prednisone group and 41 in the placebo
group). Missing data were due to incomplete or unre-
turned headache diaries. None of the patients was
excluded from participation after randomization or
did not receive medication. Patient groups available
for analysis did not differ significantly concerning
demographic and clinical characteristics (Table 1).
The trial ended after inclusion of all planned patients.
Influence of prednisone on severity of headache
and rescue medication
Primary and secondary endpoints are reported in
Table 2. Numbers of hours with severe or moderate
headache within the first 3 days (primary endpoint)
and within the first 5 days (secondary endpoint) or 14
days of withdrawal did not differ significantly between
groups. Patients in the prednisone group requested
rescue medication less frequently than those in the pla-
cebo group, which was significant concerning the first 5
days of withdrawal (p¼ 0.021, 1.1 vs. 2.3 doses), but
not significant concerning the first 14 days of with-
drawal (p¼ 0.105, 3.6 vs. 6.4 doses). Additionally, we
did not find statistically significant differences between
groups in the number of hours with mild, moderate or
severe headache within the first 3, 5 or 14 days of with-
drawal. Withdrawal headache decreased significantly
after withdrawal without differences between the pred-
nisone and placebo groups (number of hours with mod-
erate or severe headache, days-effect (days 1–3, days 4
and 5, days 6–14: p< 0.001, F¼ 43.458; group effect:
NS, ANOVA; Figure 1). Mean headache index within
Table 1. Demographic and clinical characteristics of patients available for primary endpoint evaluation.
Prednisone Placebo p
Mean age (minimum; maximum) in years 43.2 (19; 68) 40.0 (18; 66) 0.251
Sex: female; male f: 34; m: 3 f: 32; m: 9 0.093
Primary headache diagnosis 0.833
Migraine 30 34




Mean duration of primary headache in years (minimum; maximum) 26.1 (1; 50) 20.8 (3; 50) 0.066
Mean number of headache days per month during the previous 3
months (minimum; maximum)
26.4 (14; 30) 25.4 (12; 30) 0.479
Patients using acute medication before withdrawal
Triptans 19 26 NS
Analgesics 22 26 NS
Combination analgesics 9 11 NS
containing caffeine 5 5 NS
containing opioids 1 2 NS
Ergots 4 0 0.031
Others 2 1 NS
Patients taking preventive medication during withdrawal
None 13 8 NS
At least one 24 33 NS
Beta blockers 10 8 NS
Flunarizine 3 1 NS
Topiramate 13 16 NS
Valproic acid 5 4 NS
Amitriptyline, -oxide 6 6 NS
Other antidepressants 5 8 NS
Others (Tizanidine, Telmisartan, Lamotrigine) 2 5 NS
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Figure 1. Hours with moderate or severe headache decreased most within first 6–7 days of withdrawal. No statistically significant
difference between groups was observed.
Table 2. Severity of headache, other withdrawal symptoms and intake frequency of rescue medication taken.
Prednisone Placebo t-test (p)
Primary endpoint
Hours with severe or moderate headache within the first 3 days 20.9 18.2 NS
Secondary endpoints
Hours with severe or moderate headache within 5 days 29.6 27.7 NS
Hours with severe or moderate headache within 14 days 74.9 69.8 NS
Rescue medication (intake frequency) within 14 days 3.6 6.4 NS
Further results
Rescue medication (intake frequency) within the first 5 days 1.1 2.3 0.021
MHI within 3 days 1.25 1.25 NS
MHI within 5 days 0.80 0.85 NS
MHI within 14 days 0.91 0.96 NS
Further withdrawal symptoms (nausea, vomiting, photo-, phono-, osmophobia)
within 5 days
39.2 27.8 NS
MHI: mean headache index.
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3, 5 or 14 days of withdrawal did not differ significantly
between groups. We did not find any differences com-
paring patients with migraine to those with episodic
tension-type headache and comparing inpatient versus
outpatient treatment. Reduction in headache was
higher within the first 3 days in the group of patients
using triptans than in patients using other analgesics,
but differences were not statistically significantly (group
effect; p¼ 0.493; group by day effect; p¼ 0.081).
Prophylactic medication was taken by 51.3% of
patients during withdrawal. We did not find significant
differences in hours with moderate or severe headache
during 3, 5 or 14 days of withdrawal between patients
with or without preventive medication.
Treatment was well tolerated. One patient in the
verum group developed diarrhoea for 1 day during
treatment. A patient in the placebo group complained
of dry mouth and dizziness. All symptoms resolved
within 1 day. No other adverse events were reported.
Because symptoms had to be reported by patients and
were not inquired based on a list of possible adverse
events, minor adverse events might have been disre-
garded. Within the first 5 days, 39.2% of patients in
the prednisone group and 27.8% in the placebo group
complained of additional expected withdrawal symp-
toms like nausea, vomiting, photo-, phono- and osmo-
phobia (Table 2).
The following protocol deviations were identified:
two patients did not fulfil inclusion criteria because
they were older than 65 years. These patients were
included in the analysis.
Discussion
Treatment with 100mg prednisone per day over 5 days
in addition to rescue medication during withdrawal did
not reduce hours of moderate or severe headache
during withdrawal in patients with MOH. Patients trea-
ted with placebo tended to need more rescue medica-
tion than patients taking prednisone.
It was suggested several years ago that prednisone
might be effective in the treatment of withdrawal head-
ache. The idea of using prednisone was attractive
because a) it is effective in treating migrainous status
(12) and b) in contrast to drugs usually used as rescue
treatment such as intravenous aspirin, naproxen (6) or
sumatriptan (5), prednisone does not bear the risk of
supporting the vicious circle of medication overuse
headache chronification. The mode of action is not
known. Possible mechanisms are an anti-inflammatory
effect and the inhibition of cyclo-oxygenase-II. Indeed,
the first clinical observational study was promising,
reporting improvement of headache following treat-
ment with 60mg prednisone orally, but it did not com-
pare results with placebo treatment (8). Our own small
double-blind pilot study was the first randomized trial
and results favoured prednisone over placebo (11).
However, subsequent large placebo-controlled trials
by Bøe et al. (9) and Krymchantowski et al. (7) were
negative. In accordance with our current results,
patients treated with placebo did not experience fewer
hours of headache during withdrawal than patients
treated with placebo. However, in their randomized
trial, Krymchantowski et al. (7) found that patients
treated with prednisone needed less acute pain medica-
tion (rescue drugs) during withdrawal than patients
receiving naratriptan twice daily or no treatment. This
observation is strengthened by our findings. Although
headache frequency and severity are similar in both
groups, patients treated with prednisone seem to have
less need to take rescue drugs. We have to assume that
prednisone can be used to reduce intake frequency of
rescue medication during withdrawal. The following
mechanisms have to be discussed. a) Prednisone has
an analgesic effect, which is comparable to the effect
of rescue medication. b) Prednisone reduces the longing
for a rescue medication. With the assumption that
prednisone does not support the circuit that headache
leads to intake of pain medication, a theoretical advan-
tage to conventional pain medication is imaginable.
Because this effect is abolished within 14 days of
withdrawal and patients use rescue medication with
comparable frequency, we cannot give the recommen-
dation to apply prednisone for 5 days in MOH.
Combination analgesics were used infrequently in
our patient group (26%). This is within the range
of other studies in Germany (13,14). Withdrawal symp-
toms and prognosis are worse in patients using combin-
ation analgesics. More than half of the patients took
triptans. Similar to previous reports (14,15), we
observed a trend that patients overusing triptans
experienced a shorter and easier withdrawal.
However, the differences were not significant.
The strength of the study is its design (multicentre,
randomized, double-blind). We are aware of limita-
tions. We have to acknowledge a drop-out rate of
more than 10%. We have considered several possibili-
ties for improving compliance and quality of documen-
tation. Admitting patients for 14 days to the hospital is
not feasible at all centres and far from ‘real life’. We
called patients to remind them to return the headache
diary. The task of documenting the intensity of head-
ache every hour for 14 days required a high level of
motivation and discipline and probably induced
patients to drop out; but it did allow collection of valu-
able information about the course of withdrawal over
the observation time. We did not assess hours of head-
ache on days before withdrawal. Therefore, we cannot
determine whether the headache intensity and number
of hours with headache increased during withdrawal.
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Due to a very short observation period after with-
drawal of 14 days, we cannot assess how many patients
reverted to an episodic pattern after discontinuation of
medication. Information about duration of MOH years
and about earlier withdrawals could help to describe
the patient population. Unfortunately, this information
was not part of the study protocol and therefore is not
available for most patients. Initiation of prophylactic
treatment regimens during the withdrawal period
according to clinical needs and the investigators’ pref-
erences might have biased the primary outcome data.
There is still not enough evidence whether usage of
prophylactic medication should be started on the day
of withdrawal or after a few weeks, when the vicious
circle of MOH has been broken. When this trial was
started, it was common practice in Europe to first inter-
rupt the overuse and begin with prophylactics later, if
necessary. This was due to the awareness that prophy-
lactics during overuse do not reduce headache fre-
quency. Only recently it was shown that topiramate is
effective even in patients overusing medication (16).
We conclude finally that our study suggests that
prednisone is not effective in the treatment of with-
drawal headache in patients with medication overuse
headache, but can reduce intake of rescue medication
during withdrawal.
Clinical implications
. To investigate the efficacy of prednisone for treatment of withdrawal headache in patients with medication
overuse headache (MOH).
. During withdrawal in MOH, prednisone reduces rescue medication without decreasing the severity and
duration of withdrawal headache.
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